Close Menu
Home » PrimeraDx Developing Assays for Eli Lilly's Drug Development Programs

PrimeraDx Developing Assays for Eli Lilly's Drug Development Programs

Jun 26, 2012
|
staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm PrimeraDx today announced a deal with Eli Lilly to develop diagnostics in support of the drug firm's therapeutic development programs.

The multiyear deal calls for the two firms to collaborate on the development of multiplex assays on PrimeraDx's ICEPlex System, an automated, high-throughput real-time PCR and capillary electrophoresis instrument. Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Ah, That's What It Is

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

Billions Requested

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

What to Do

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

PNAS Papers on Heart Transplant Rejection, CAR-T Profiling, Thiopurine Toxicity Variants

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.

Mar
18
Featured Webinar

Comparison of Genome-Wide versus Targeted cfDNA Testing for First-Line Prenatal Screening: Real-World Data

Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.